Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial

Abstract

Escitalopram was well tolerated, safe, and efficacious. Escitalopram can be used with confidence to treat patients with MDD in Canadian primary-care settings.

Anticipated Outcomes from Introduction of 5-HTTLPR Genotyping for Depressed Patients: An Expert Delphi Analysis

“…Remission rates after 2 months were obtained from RCTs performed by Montgomery et al [20], Bielski et al [23], Einarson [24], Lepola et al [25], Sir et al [26], and Wade et al [27], together with epidemiological studies by Keller et al [21] and Patten [22]. Data after 3 months were obtained from studies performed by Chokka and Legault [28], Keller et al [21], Patten [22], and Spijker et al [29]. Studies performed by Wade et al [27], Chokka and Legault [28], Keller et al [21], Patten [22], and Spijker et al [29] provided data about remission after 6 months.…”

“…Data after 3 months were obtained from studies performed by Chokka and Legault [28], Keller et al [21], Patten [22], and Spijker et al [29]. Studies performed by Wade et al [27], Chokka and Legault [28], Keller et al [21], Patten [22], and Spijker et al [29] provided data about remission after 6 months.…”

Quality of life and functioning of Hispanic patients with Major Depressive Disorder before and after treatment

“…In recent years, there has been increased attention on enhancing QOL, as it is strongly correlated with greater MDD symptom severity via socio-demographic factors such as employment, education, race and medical insurance status (Trivedi et al, 2006). Additionally, a number of studies have demonstrated that antidepressant monotherapy improves QOL in MDD, as measured by various validated assessment tools (Chokka & Legault, 2008; Demyttenaere, Andersen, & Reines, 2008; Ishak et al, 2011; Kocsis et al, 2002; Steiner et al, 2017).…”